Close Menu
Money MechanicsMoney Mechanics
    What's Hot

    29% of U.S. Home Purchases Are Made in Cash, Essentially Flat From a Year Ago

    October 17, 2025

    Amex Stock Hits Record High; Oracle and Newmont Plunge

    October 17, 2025

    NextDecade approves $6.7 billion expansion of Rio Grande LNG – Oil & Gas 360

    October 17, 2025
    Facebook X (Twitter) Instagram
    Trending
    • 29% of U.S. Home Purchases Are Made in Cash, Essentially Flat From a Year Ago
    • Amex Stock Hits Record High; Oracle and Newmont Plunge
    • NextDecade approves $6.7 billion expansion of Rio Grande LNG – Oil & Gas 360
    • New Round Lot Rules Help Issuers with High-Priced Stocks
    • Tariffs Have Pushed Up Inflation, And There Are More Price Hikes To Come, Economists Say
    • Oracle’s Stock Was a Big September Winner. Why Has It Turned South?
    • How the New Tax Bill Could Boost Your Refund Next Year
    • How To Decide If The Foundation Of Your Estate Plan Should Be A Will Or A Trust
    Facebook X (Twitter) Instagram
    Money MechanicsMoney Mechanics
    • Home
    • Markets
      • Stocks
      • Crypto
      • Bonds
      • Commodities
    • Economy
      • Fed & Rates
      • Housing & Jobs
      • Inflation
    • Earnings
      • Banks
      • Energy
      • Healthcare
      • IPOs
      • Tech
    • Investing
      • ETFs
      • Long-Term
      • Options
    • Finance
      • Budgeting
      • Credit & Debt
      • Real Estate
      • Retirement
      • Taxes
    • Opinion
    • Guides
    • Tools
    • Resources
    Money MechanicsMoney Mechanics
    Home»Guides & How-To»Tylenol Maker Kenvue’s Stock Slumps Following Report RFK Jr. Will Link It to Autism
    Guides & How-To

    Tylenol Maker Kenvue’s Stock Slumps Following Report RFK Jr. Will Link It to Autism

    Money MechanicsBy Money MechanicsSeptember 5, 2025No Comments2 Mins Read
    Facebook Twitter LinkedIn Telegram Pinterest Tumblr Reddit WhatsApp Email
    Tylenol Maker Kenvue’s Stock Slumps Following Report RFK Jr. Will Link It to Autism
    Share
    Facebook Twitter LinkedIn Pinterest Email



    Key Takeaways

    • Kenvue’s stock slumped Friday after The Wall Street Journal reported federal officials plan to link use of one of its products, Tylenol, with autism.
    • Kenvue said it has “continuously evaluated” Tylenol and believes there is no link between its active ingredient, acetaminophen, and autism.
    • A number of other over-the-counter drugs contain acetaminophen, but their manufacturers’ stocks haven’t taken the same hit as Kenvue.

    Shares of Tylenol-maker Kenvue (KVUE) plunged over 9% Friday following a report that federal health officials may link use of the painkiller during pregnancy to autism.

    Health Secretary Robert F. Kennedy Jr. plans to announce a report saying the use of Tylenol during pregnancy may be one of several causes of autism, The Wall Street Journal reported Friday afternoon, citing people familiar with the matter. A spokesperson for the Department of Health and Human Services told Investopedia that it is “using gold-standard science to get to the bottom of America’s unprecedented rise in autism rates,” and that until the final report is released, any claims about its contents should be treated as speculation.

    Kenvue said the active ingredient in Tylenol, acetaminophen, was studied for more than a decade by the U.S. Federal Drug Administration, which concluded research hasn’t supported a causal link between acetaminophen and autism.

    “Nothing is more important to us than the health and safety of the people who use our products,” Kenvue said in a statement. “We have continuously evaluated the science and continue to believe there is no causal link between acetaminophen use during pregnancy and autism.”

    RFK Jr., who has pledged to identify the cause of autism, has also previously voiced concerns about vaccines and other medical treatments deemed safe by the medical establishment.

    A number of other painkillers and congestion relievers available without prescriptions contain acetaminophen, including Benadryl, Sudafed, DayQuil, Excedrin, NyQuil, Robitussin and Vicks, according to BeMedWise, a patient safety and education group. Benadryl and Sudafed are sold by Kenvue in the U.S., according to Kenvue’s website.

    Shares of manufacturers for many of the other products with acetaminophen haven’t taken the same hit as Kenvue. Haleon (HLN), which sells Excedrin and Robitussin, was recently off by less than 1%, while shares of Procter & Gamble (PG), which sells Vicks, DayQuil and NyQuil, finished Friday’s session up less than 1%.



    Source link

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email
    Previous ArticleKiplinger News Quiz, September 5, 2025
    Next Article Frontier GoWild! Pass Review 2025: Is the $299 All-You-Can-Fly Deal Worth It?
    Money Mechanics
    • Website

    Related Posts

    Oracle, Newmont, Kenvue, American Express, and More

    October 17, 2025

    You May Want To Think Twice Before Selling These Four Assets in Retirement

    October 17, 2025

    4 Steps Clients Should Take to Maximize Their FSA Accounts

    October 17, 2025
    Add A Comment
    Leave A Reply Cancel Reply

    Top Posts

    29% of U.S. Home Purchases Are Made in Cash, Essentially Flat From a Year Ago

    October 17, 2025

    Amex Stock Hits Record High; Oracle and Newmont Plunge

    October 17, 2025

    NextDecade approves $6.7 billion expansion of Rio Grande LNG – Oil & Gas 360

    October 17, 2025

    New Round Lot Rules Help Issuers with High-Priced Stocks

    October 17, 2025

    Subscribe to Updates

    Please enable JavaScript in your browser to complete this form.
    Loading

    At Money Mechanics, we believe money shouldn’t be confusing. It should be empowering. Whether you’re buried in debt, cautious about investing, or simply overwhelmed by financial jargon—we’re here to guide you every step of the way.

    Facebook X (Twitter) Instagram Pinterest YouTube
    Links
    • About Us
    • Contact Us
    • Disclaimer
    • Privacy Policy
    • Terms and Conditions
    Resources
    • Breaking News
    • Economy & Policy
    • Finance Tools
    • Fintech & Apps
    • Guides & How-To
    Get Informed

    Subscribe to Updates

    Please enable JavaScript in your browser to complete this form.
    Loading
    Copyright© 2025 TheMoneyMechanics All Rights Reserved.
    • Breaking News
    • Economy & Policy
    • Finance Tools
    • Fintech & Apps
    • Guides & How-To

    Type above and press Enter to search. Press Esc to cancel.